共 229 条
[31]
Harbison CT(2007)Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data ASCO Meet Abstr 25 4037-undefined
[32]
Hart LL(2008)Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21 Contemp clin trials 29 527-undefined
[33]
Awad M(2010)Analysis of the yield of phase II combination therapy trials in medical oncology Clin Cancer Res 16 5296-undefined
[34]
Xu LA(undefined)undefined undefined undefined undefined-undefined
[35]
Horak CE(undefined)undefined undefined undefined undefined-undefined
[36]
Dakhil S(undefined)undefined undefined undefined undefined-undefined
[37]
Hermann RC(undefined)undefined undefined undefined undefined-undefined
[38]
Lynch TJ(undefined)undefined undefined undefined undefined-undefined
[39]
Weber MR(undefined)undefined undefined undefined undefined-undefined
[40]
O'Byrne KJ(undefined)undefined undefined undefined undefined-undefined